Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000071.xml
Download PDF
Semin Neurol 2017; 37(02): 176-185
DOI: 10.1055/s-0037-1601568
DOI: 10.1055/s-0037-1601568
Review Article
Management of Autonomic Dysfunction in Parkinson's Disease
Further Information
Publication History
Publication Date:
16 May 2017 (online)
Abstract
Autonomic dysfunction is a frequent and important nonmotor feature of Parkinson's disease (PD). Autonomic dysfunction in PD spans a broad clinical spectrum. Cardiovascular dysfunction is characterized most prominently by orthostatic hypotension. Gastrointestinal dysfunction can involve virtually all levels of the gastrointestinal tract. Urinary dysfunction can entail either too frequent voiding or difficulty voiding. Sexual dysfunction is frequent and frustrating for both the patient and the partner. Alterations in sweating and body temperature are not widely recognized, but often are present. The presence of effective treatment for at least some aspects of autonomic dysfunction makes it vitally important that the assessment of autonomic dysfunction be a regular component of the neurologic history and examination for individuals with PD.
-
References
- 1 Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF. Autonomic dysfunction in Parkinson's disease: a comprehensive symptom survey. Parkinsonism Relat Disord 2002; 8 (4) 277-284
- 2 Khoo TK, Yarnall AJ, Duncan GW , et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013; 80 (3) 276-281
- 3 Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson's disease. Mov Disord 2009; 24 (6) 793-800
- 4 Pfeiffer RF. Autonomic dysfunction in Parkinson's disease. Expert Rev Neurother 2012; 12 (6) 697-706
- 5 Amino T, Orimo S, Itoh Y, Takahashi A, Uchihara T, Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 2005; 15 (1) 29-34
- 6 Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord 2009; 24 (Suppl. 02) S732-S741
- 7 Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord 2012; 18 (5) 494-500
- 8 Haensch CA, Lerch H, Jörg J, Isenmann S. Cardiac denervation occurs independent of orthostatic hypotension and impaired heart rate variability in Parkinson's disease. Parkinsonism Relat Disord 2009; 15 (2) 134-137
- 9 Katagiri A, Asahina M, Araki N , et al. Myocardial (123)I-MIBG uptake and cardiovascular autonomic function in Parkinson's disease. Parkinsons Dis 2015; 2015: 805351
- 10 Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2011; 17 (10) 724-729
- 11 Senard JM, Raï S, Lapeyre-Mestre M , et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63 (5) 584-589
- 12 Merola A, Romagnolo A, Rosso M , et al. Orthostatic hypotension in Parkinson's disease: does it matter if asymptomatic?. Parkinsonism Relat Disord 2016; 33: 65-71
- 13 Goldstein DS. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 2006; 16 (1) 46-54
- 14 Kim JS, Lee SH, Oh YS , et al. Cardiovascular autonomic dysfunction in mild and advanced Parkinson's disease. J Mov Disord 2016; 9 (2) 97-103
- 15 Strano S, Fanciulli A, Rizzo M , et al. Cardiovascular dysfunction in untreated Parkinson's disease: A multi-modality assessment. J Neurol Sci 2016; 370: 251-255
- 16 Rascol O, Perez-Lloret S, Damier P , et al. Falls in ambulatory non-demented patients with Parkinson's disease. J Neural Transm (Vienna) 2015; 122 (10) 1447-1455
- 17 Gibbons CH, Schmidt P, Biaggioni I , et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol 2017
- 18 Espay AJ, LeWitt PA, Hauser RA, Merola A, Masellis M, Lang AE. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. Lancet Neurol 2016; 15 (9) 954-966
- 19 Rowell LB, Detry JM, Blackmon JR, Wyss C. Importance of the splanchnic vascular bed in human blood pressure regulation. J Appl Physiol 1972; 32 (2) 213-220
- 20 Figueroa JJ, Singer W, Sandroni P , et al. Effects of patient-controlled abdominal compression on standing systolic blood pressure in adults with orthostatic hypotension. Arch Phys Med Rehabil 2015; 96 (3) 505-510
- 21 Low PA, Tomalia VA. Orthostatic hypotension: mechanisms, causes, management. J Clin Neurol 2015; 11 (3) 220-226
- 22 Hussain RM, McIntosh SJ, Lawson J, Kenny RA. Fludrocortisone in the treatment of hypotensive disorders in the elderly. Heart 1996; 76 (6) 507-509
- 23 McClellan KJ, Wiseman LR, Wilde MI. Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging 1998; 12 (1) 76-86
- 24 Kaufmann H, Norcliffe-Kaufmann L, Hewitt LA, Rowse GJ, White WB. Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood pressure in patients with neurogenic orthostatic hypotension. J Am Soc Hypertens 2016; 10 (10) 819-826
- 25 Sharabi Y, Goldstein DS. Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. J Neurol Sci 2011; 310 (1-2): 123-128
- 26 Umehara T, Nakahara A, Matsuno H, Toyoda C, Oka H. Predictors of postprandial hypotension in elderly patients with de novo Parkinson's disease. J Neural Transm (Vienna) 2016; 123 (11) 1331-1339
- 27 Cicconetti P, Ciotti V, Monteforte G , et al. Circadian blood pressure pattern and cognitive function in newly diagnosed older hypertensives. Blood Press 2003; 12 (3) 168-174
- 28 Routledge F, McFetridge-Durdle J. Nondipping blood pressure patterns among individuals with essential hypertension: a review of the literature. Eur J Cardiovasc Nurs 2007; 6 (1) 9-26
- 29 Sommer S, Aral-Becher B, Jost W. Nondipping in Parkinson's disease. Parkinsons Dis 2011; 2011: 897586
- 30 Fanciulli A, Göbel G, Ndayisaba JP , et al. Supine hypertension in Parkinson's disease and multiple system atrophy. Clin Auton Res 2016; 26 (2) 97-105
- 31 Umehara T, Matsuno H, Toyoda C, Oka H. Clinical characteristics of supine hypertension in de novo Parkinson disease. Clin Auton Res 2016; 26 (1) 15-21
- 32 Li K, Reichmann H, Ziemssen T. Recognition and treatment of autonomic disturbances in Parkinson's disease. Expert Rev Neurother 2015; 15 (10) 1189-1203
- 33 Parkinson J. An Essay on the Shaking Palsy. Whittingham and Rowland. London, 2017
- 34 Eadie MJ, Tyrer JH. Alimentary disorder in parkinsonism. Australas Ann Med 1965; 14: 13-22
- 35 Korczyn AD. Autonomic nervous system disturbances in Parkinson's disease. Adv Neurol 1990; 53: 463-468
- 36 Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991; 6 (2) 151-156
- 37 Jost WH, Schimrigk K. Constipation in Parkinson's disease. Klin Wochenschr 1991; 69: 906-909
- 38 Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2003; 2 (2) 107-116
- 39 Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology 1984; 87 (4) 848-856
- 40 Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987; 37 (7) 1253-1255
- 41 Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 1990; 79 (6) 581-583
- 42 Singaram C, Ashraf W, Gaumnitz EA , et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995; 346 (8979): 861-864
- 43 Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain?. J Neuropathol Exp Neurol 2002; 61 (5) 413-426
- 44 Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006; 396 (1) 67-72
- 45 Keshavarzian A, Green SJ, Engen PA , et al. Colonic bacterial composition in Parkinson's disease. Mov Disord 2015; 30 (10) 1351-1360
- 46 Scheperjans F, Aho V, Pereira PA , et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 2015; 30 (3) 350-358
- 47 Unger MM, Spiegel J, Dillmann KU , et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord 2016; 32: 66-72
- 48 Felice VD, Quigley EM, Sullivan AM, O'Keeffe GW, O'Mahony SM. Microbiota-gut-brain signalling in Parkinson's disease: implications for non-motor symptoms. Parkinsonism Relat Disord 2016; 27: 1-8
- 49 Sampson TR, Debelius JW, Thron T , et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 2016; 167 (6) 1469-1480.e12
- 50 Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson's disease. Eur J Clin Nutr 1992; 46 (12) 879-884
- 51 Wang G, Wan Y, Cheng Q , et al. Malnutrition and associated factors in Chinese patients with Parkinson's disease: Results from a pilot investigation. Parkinsonism Relat Disord 2010; 16 (2) 119-123
- 52 Markaki E, Ellul J, Kefalopoulou Z , et al. The role of ghrelin, neuropeptide Y and leptin peptides in weight gain after deep brain stimulation for Parkinson's disease. Stereotact Funct Neurosurg 2012; 90 (2) 104-112
- 53 Novakova L, Haluzik M, Jech R, Urgosik D, Ruzicka F, Ruzicka E. Hormonal regulators of food intake and weight gain in Parkinson's disease after subthalamic nucleus stimulation. Neuroendocrinol Lett 2011; 32 (4) 437-441
- 54 Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007; 69 (4) 333-341
- 55 Müller B, Larsen JP, Wentzel-Larsen T, Skeie GO, Tysnes OB ; Parkwest Study Group. Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: frequent but mild. Mov Disord 2011; 26 (1) 65-72
- 56 Karakoc M, Yon MI, Cakmakli GY , et al. Pathophysiology underlying drooling in Parkinson's disease: oropharyngeal bradykinesia. Neurol Sci 2016; 37 (12) 1987-1991
- 57 Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002; 17 (6) 1318-1320
- 58 Narayanaswami P, Geisbush T, Tarulli A , et al. Drooling in Parkinson's disease: a randomized controlled trial of incobotulinum toxin A and meta-analysis of botulinum toxins. Parkinsonism Relat Disord 2016; 30: 73-77
- 59 Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004; 62 (1) 37-40
- 60 Clifford TJ, Warsi MJ, Burnett CA, Lamey PJ. Burning mouth in Parkinson's disease sufferers. Gerodontology 1998; 15 (2) 73-78
- 61 Bonenfant D, Rompré PH, Rei N , et al. Characterization of burning mouth syndrome in patients with Parkinson's disease. J Oral Facial Pain Headache 2016; 30 (4) 318-322
- 62 Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. In: Pfeiffer RF, Wszolek ZK, Ebadi M, , eds. Parkinson's Disease. 2nd ed. Boca Raton, FL: CRC Press; 2013: 309-326
- 63 Jones CA, Ciucci MR. Multimodal swallowing evaluation with high-resolution manometry reveals subtle swallowing changes in early and mid-stage Parkinson disease. J Parkinsons Dis 2016; 6 (1) 197-208
- 64 Gross RD, Atwood Jr CW, Ross SB, Eichhorn KA, Olszewski JW, Doyle PJ. The coordination of breathing and swallowing in Parkinson's disease. Dysphagia 2008; 23 (2) 136-145
- 65 Byrne KG, Pfeiffer R, Quigley EM. Gastrointestinal dysfunction in Parkinson's disease. A report of clinical experience at a single center. J Clin Gastroenterol 1994; 19 (1) 11-16
- 66 Suttrup I, Warnecke T. Dysphagia in Parkinson's disease. Dysphagia 2016; 31 (1) 24-32
- 67 Menezes C, Melo A. Does levodopa improve swallowing dysfunction in Parkinson's disease patients?. J Clin Pharm Ther 2009; 34 (6) 673-676
- 68 Warnecke T, Suttrup I, Schröder JB , et al. Levodopa responsiveness of dysphagia in advanced Parkinson's disease and reliability testing of the FEES-levodopa-test. Parkinsonism Relat Disord 2016; 28: 100-106
- 69 Restivo DA, Palmeri A, Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson's disease. N Engl J Med 2002; 346 (15) 1174-1175
- 70 Born LJ, Harned RH, Rikkers LF, Pfeiffer RF, Quigley EM. Cricopharyngeal dysfunction in Parkinson's disease: role in dysphagia and response to myotomy. Mov Disord 1996; 11 (1) 53-58
- 71 Troche MS, Okun MS, Rosenbek JC , et al. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial. Neurology 2010; 75 (21) 1912-1919
- 72 Byeon H. Effect of simultaneous application of postural techniques and expiratory muscle strength training on the enhancement of the swallowing function of patients with dysphagia caused by Parkinson's disease. J Phys Ther Sci 2016; 28 (6) 1840-1843
- 73 Pasricha PJ, Parkman HP. Gastroparesis: definitions and diagnosis. Gastroenterol Clin North Am 2015; 44 (1) 1-7
- 74 Heetun ZS, Quigley EM. Gastroparesis and Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2012; 18 (5) 433-440
- 75 Tanaka Y, Kato T, Nishida H , et al. Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the 13C-acetate breath test. J Neurol 2011; 258 (3) 421-426
- 76 Soykan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997; 12 (6) 952-957
- 77 Leelakanok N, Holcombe A, Schweizer ML. Domperidone and risk of ventricular arrhythmia and cardiac death: a systematic review and meta-analysis. Clin Drug Investig 2016; 36 (2) 97-107
- 78 Buffery PJ, Strother RM. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. N Z Med J 2015; 128 (1416): 66-74
- 79 Gil RA, Hwynn N, Fabian T, Joseph S, Fernandez HH. Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients. Parkinsonism Relat Disord 2011; 17 (4) 285-287
- 80 Lembo A, Camilleri M, McCallum R , et al; RM-131-004 Trial Group. Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis. Gastroenterology 2016; 151 (1) 87-96.e6
- 81 Camilleri M. Novel diet, drugs, and gastric interventions for gastroparesis. Clin Gastroenterol Hepatol 2016; 14 (8) 1072-1080
- 82 Fasano A, Bove F, Gabrielli M , et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013; 28 (9) 1241-1249
- 83 Tan AH, Mahadeva S, Thalha AM , et al. Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism Relat Disord 2014; 20 (5) 535-540
- 84 Niu XL, Liu L, Song ZX , et al. Prevalence of small intestinal bacterial overgrowth in Chinese patents with Parkinson's disease. J Neural Transm (Vienna) 2016; 123: 1381-1386
- 85 Quigley EM. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol 2014; 30 (2) 141-146
- 86 Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2011; 17 (1) 10-15
- 87 Knudsen K, Krogh K, Østergaard K, Borghammer P. Constipation in Parkinson's disease: subjective symptoms, objective markers, and new perspectives. Mov Disord 2017; 32 (1) 94-105
- 88 Jost WH, Schimrigk K. Constipation in Parkinson's disease. Klin Wochenschr 1991; 69 (20) 906-909
- 89 Savica R, Carlin JM, Grossardt BR , et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009; 73 (21) 1752-1758
- 90 Svensson E, Henderson VW, Borghammer P, Horváth-Puhó E, Sørensen HT. Constipation and risk of Parkinson's disease: a Danish population-based cohort study. Parkinsonism Relat Disord 2016; 28: 18-22
- 91 Lin CH, Lin JW, Liu YC, Chang CH, Wu RM. Risk of Parkinson's disease following severe constipation: a nationwide population-based cohort study. Parkinsonism Relat Disord 2014; 20 (12) 1371-1375
- 92 Toebosch S, Tudyka V, Masclee A, Koek G. Treatment of recurrent sigmoid volvulus in Parkinson's disease by percutaneous endoscopic colostomy. World J Gastroenterol 2012; 18 (40) 5812-5815
- 93 Blackley S, Maguire C, Daniels T. Seven cases of sigmoid volvulus in Parkinson's disease. J R Coll Physicians Edinb 2016; 46 (3) 157-159
- 94 Ondo WG, Kenney C, Sullivan K , et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012; 78 (21) 1650-1654
- 95 Sadjadpour K. Pyridostigmine bromide and constipation in Parkinson's disease. JAMA 1983; 249 (9) 1148
- 96 Sakakibara R, Doi H, Sato M , et al. Nizatidine ameliorates slow transit constipation in Parkinson's disease. J Am Geriatr Soc 2015; 63 (2) 399-401
- 97 Pagano G, Tan EE, Haider JM, Bautista A, Tagliati M. Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease. Parkinsonism Relat Disord 2015; 21 (2) 120-125
- 98 Chiu CM, Wang CP, Sung WH, Huang SF, Chiang SC, Tsai PY. Functional magnetic stimulation in constipation associated with Parkinson's disease. J Rehabil Med 2009; 41 (13) 1085-1089
- 99 McClurg D, Walker K, Aitchison P , et al. Abdominal massage for the relief of constipation in people with Parkinson's: a qualitative study. Parkinsons Dis 2016; 2016: 4842090
- 100 Barichella M, Pacchetti C, Bolliri C , et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT. Neurology 2016; 87 (12) 1274-1280
- 101 Bassotti G, Maggio D, Battaglia E , et al. Manometric investigation of anorectal function in early and late stage Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 68 (6) 768-770
- 102 Cersosimo MG, Raina GB, Pecci C , et al. Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. J Neurol 2013; 260 (5) 1332-1338
- 103 Tateno F, Sakakibara R, Yokoi Y , et al. Levodopa ameliorated anorectal constipation in de novo Parkinson's disease: the QL-GAT study. Parkinsonism Relat Disord 2011; 17 (9) 662-666
- 104 Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol 1993; 33 (5) 490-493
- 105 Albanese A, Brisinda G, Bentivoglio AR, Maria G. Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am J Gastroenterol 2003; 98 (6) 1439-1440
- 106 McDonald C, Winge K, Burn DJ. Lower urinary tract symptoms in Parkinson's disease: prevalence, aetiology and management. Parkinsonism Relat Disord 2017; 35: 8-16
- 107 Martinez-Martin P, Schapira AH, Stocchi F , et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007; 22 (11) 1623-1629
- 108 O'Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord 2008; 23 (1) 101-106
- 109 Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006; 21 (6) 737-745
- 110 Singer C, Moore H. Urological dysfunction. In: Pfeiffer RF, Wszolek ZK, Ebadi M, eds. Parkinson's Disease. 2nd ed. Boca Raton, FL: CRC Press; 2013: 327-341
- 111 Ragab MM, Mohammed ES. Idiopathic Parkinson's disease patients at the urologic clinic. Neurourol Urodyn 2011; 30 (7) 1258-1261
- 112 Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008; 62 (11) 1792-1800
- 113 Zesiewicz TA, Evatt M, Vaughan CP , et al; Non-Motor Working Group of the Parkinson Study Group (PSG). Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism Relat Disord 2015; 21 (5) 514-520
- 114 Kulaksizoglu H, Parman Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease. Parkinsonism Relat Disord 2010; 16 (8) 531-534
- 115 Giannantoni A, Conte A, Proietti S , et al. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol 2011; 186 (3) 960-964
- 116 Mock S, Osborn DJ, Brown ET , et al. The impact of pallidal and subthalamic deep brain stimulation on urologic function in Parkinson's disease. Neuromodulation 2016; 19 (7) 717-723
- 117 Moore H, Singer C. Urological dysfunction. In: Pfeiffer RF, Bodis-Wollner I, , eds. Parkinson's Disease and Nonmotor Dysfunction. 2nd ed. New York, NY: Humana Press; 2013: 187-200
- 118 Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic findings in Parkinson's disease. J Urol 1983; 129 (1) 80-83
- 119 Galloway NT. Urethral sphincter abnormalities in Parkinsonism. Br J Urol 1983; 55 (6) 691-693
- 120 Stocchi F, Carbone A, Inghilleri M , et al. Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 1997; 62 (5) 507-511
- 121 van Hees PJ, van der Plas AA, van Ek GF , et al. Discussing sexuality with patients with Parkinson's disease: a survey among Dutch neurologists. J Neural Transm (Vienna) 2017; 124 (3) 361-368
- 122 Bronner G. Sexual problems in Parkinson's disease: the multidimensional nature of the problem and of the intervention. J Neurol Sci 2011; 310 (1-2): 139-143
- 123 Jitkritsadakul O, Jagota P, Bhidayasiri R. Postural instability, the absence of sexual intercourse in the past month, and loss of libido are predictors of sexual dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2015; 21 (1) 61-67
- 124 Koller WC, Vetere-Overfield B, Williamson A, Busenbark K, Nash J, Parrish D. Sexual dysfunction in Parkinson's disease. Clin Neuropharmacol 1990; 13 (5) 461-463
- 125 Sakakibara R, Kishi M, Ogawa E , et al. Bladder, bowel, and sexual dysfunction in Parkinson's disease. Parkinsons Dis 2011; 2011: 924605
- 126 Deng X, Xiao B, Li HH , et al. Sexual dysfunction is associated with postural instability gait difficulty subtype of Parkinson's disease. J Neurol 2015; 262 (11) 2433-2439
- 127 Ferrucci R, Panzeri M, Ronconi L , et al. Abnormal sexuality in Parkinson's disease: fact or fancy?. J Neurol Sci 2016; 369: 5-10
- 128 Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord 2000; 15 (2) 305-308
- 129 Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001; 71 (3) 371-374
- 130 Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol 2002; 59 (5) 807-811
- 131 Simonsen U, Comerma-Steffensen S, Andersson KE. Modulation of dopaminergic pathways to treat erectile dysfunction. Basic Clin Pharmacol Toxicol 2016; 119 (Suppl. 03) 63-74
- 132 Bronner G, Aharon-Peretz J, Hassin-Baer S. Sexuality in patients with Parkinson's disease, Alzheimer's disease, and other dementias. Handb Clin Neurol 2015; 130: 297-323
- 133 Langston JW, Forno LS. The hypothalamus in Parkinson disease. Ann Neurol 1978; 3 (2) 129-133
- 134 Beach TG, Adler CH, Sue LI , et al; Arizona Parkinson's Disease Consortium. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010; 119 (6) 689-702
- 135 Kataoka H, Ueno S. Severe cold lower limbs in patients with Parkinson's disease during the summer. Neurol Int 2016; 8 (4) 6676
- 136 Shindo K, Kobayashi F, Miwa M, Nagasaka T, Takiyama Y, Shiozawa Z. Temporal prolongation of decreased skin blood flow causes cold limbs in Parkinson's disease. J Neural Transm (Vienna) 2013; 120 (3) 445-451
- 137 Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology 1976; 26 (5) 423-429
- 138 Turkka JT, Myllylä VV. Sweating dysfunction in Parkinson's disease. Eur Neurol 1987; 26 (1) 1-7
- 139 De Marinis M, Stocchi F, Testa SR, De Pandis F, Agnoli A. Alterations of thermoregulation in Parkinson's disease. Funct Neurol 1991; 6 (3) 279-283
- 140 Lipp A, Sandroni P, Ahlskog JE , et al. Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch Neurol 2009; 66 (6) 742-750
- 141 Pursiainen V, Haapaniemi TH, Korpelainen JT, Sotaniemi KA, Myllylä VV. Sweating in Parkinsonian patients with wearing-off. Mov Disord 2007; 22 (6) 828-832
- 142 Sage JI, Mark MH. Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile. Ann Neurol 1995; 37 (1) 120-122
- 143 van Hilten BJ, Roos RA. The continuum of hyperthermic syndromes with impaired dopaminergic activity. Arch Intern Med 1992; 152 (8) 1727-1730 , 1730
- 144 Reutens DC, Harrison WB, Goldswain PR. Neuroleptic malignant syndrome complicating levodopa withdrawal. Med J Aust 1991; 155 (1) 53-54
- 145 Bonnici A, Ruiner CE, St-Laurent L, Hornstein D. An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay. Ann Pharmacother 2010; 44 (9) 1504-1507
- 146 Whitman CB, Ablordeppey E, Taylor B. Levodopa withdrawal presenting as fever in a critically ill patient receiving concomitant enteral nutrition. J Pharm Pract 2016; 29 (6) 574-578
- 147 Pfeiffer RF, Sucha EL. “On-off”-induced lethal hyperthermia. Mov Disord 1989; 4 (4) 338-341
- 148 Trachani E, Constantoyannis C, Sirrou V, Kefalopoulou Z, Markaki E, Chroni E. Effects of subthalamic nucleus deep brain stimulation on sweating function in Parkinson's disease. Clin Neurol Neurosurg 2010; 112 (3) 213-217
- 149 Sanghera MK, Ward C, Stewart RM, Mewes K, Simpson RK, Lai EC. Alleviation of drenching sweats following subthalamic deep brain stimulation in a patient with Parkinson's disease--a case report. J Neurol Sci 2009; 285 (1-2): 246-249